Diabetes News

Glycemic control, weight, and treatment satisfaction improved after switching from sitagliptin to liraglutide, albeit with a transient increase in gastrointestinal reactions (Diabetes Care)

The results from both studies confirm that imeglimin displays a superior benefit : risk profile compared with metformin in type 2 diabetes patients. The encouraging tolerability profile of imeglimin could make it suitable for combination with other classes of antidiabetic agents and may increase availability to a wider patient population (Diabetes, Obesity and Metabolism)

An increased risk of new onset treated diabetes was found in those treated with statins showing significant duration and dose effect. Further study is required to confirm this association (British Journal of Clinical Pharmacology)

The new app is called NICE BNF and has been developed to provide easy access to the latest up-to-date prescribing information from the BNF – the most widely-used medicines information resource within the NHS. The app is available to download for free to health and care professionals via the Apple App Store and Google Play Store. Users will need to enter their NHS Athens user name and password to activate the app and download the content (Hopspital Pharmacy)

Our results support the option of addition of basal insulin in patients with type 2 diabetes inadequately controlled by metformin (The Lancet)

Despite well-documented benefits of timely glycaemic control and consensus guidelines encouraging earlier use of insulin, considerable clinical inertia exists with respect to initiating appropriate insulin therapy in people with T2DM. Considerable regional differences exist in the timing of insulin initiation and in the use of OADs (Diabetes, Obesity and Metabolism)

Milestone reflects the commitment of Boehringer Ingelheim and Eli Lilly and Company in bringing new diabetes medicines to patients around the world who need them (Lilly)